Evaluation of dapagliflozin taken twice-daily

Inclusion Criteria

• - Provision of informed consent prior to any study specific procedures
• - Diagnosis of T2DM
• - Current antihyperglycaemic treatment with metformin immediate release formulation monotherapy >/= 1500 mg/day at a stable dose for at least 10 weeks prior to enrolment. Other treatment with OADs within the 10 weeks prior to enrolment is not permitted.
• - HbA1c ≥ 6.7% and ≤10.5%, based on central laboratory values from Screening Visit, and Enrolment Visit 1.